SCHEMBL16166360

SCHEMBL16166360

CC(=O)OCCCN1CCc2cc(CC(C)[N+](=O)[O-])cc(C#N)c21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 19/20 0.35
ADRA1A P35348 19/20 0.35
ADRA1B P35368 19/20 0.35
ADRB2 P07550 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
DRD2 P14416 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
DRD1 P21728 1/20 0.33
DRD4 P21917 1/20 0.33
PTGS1 P23219 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
HTR7 P34969 1/20 0.33
HRH1 P35367 1/20 0.33
OPRM1 P35372 1/20 0.33
DRD3 P35462 1/20 0.33
HTR2B P41595 1/20 0.33
SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16422039 0.92 ADRA1D (0.34) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL2547252 0.88 ADRA1D (0.37) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL16171285 0.87 ADRA1D (0.40) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL18902584 0.87 ADRA1D (0.39) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL18157053 0.87 ADRA1D (0.37) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL16166283 0.87 ADRA1D (0.37) ADRA1DADRA1AADRA1BMAPT
SCHEMBL17516016 0.86 CRHR1 (0.35) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL16166466 0.85 ADRA1D (0.33) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL16166529 0.85 ADRA1D (0.31) ADRA1DADRA1AADRA1BMAPT
SCHEMBL526176 0.83 MAPT (0.48) ADRA1DADRA1AADRA1BNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239833-B2 Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin MANKIND PHARMA LTD. (IN) 2019-03-26 US disclosed
US-10239833-B2 Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin MANKIND PHARMA LTD. (IN) 2019-03-26 US disclosed
US-20180111901-A1 Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin MANKIND PHARMA LTD. (IN) 2018-04-26 US disclosed
US-20180111901-A1 Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin MANKIND PHARMA LTD. (IN) 2018-04-26 US disclosed
US-20180111901-A1 Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin MANKIND PHARMA LTD. (IN) 2018-04-26 US disclosed
EP-2984070-B1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES MANKIND PHARMA LTD (IN) 2018-01-17 EP disclosed
EP-2984070-B1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES MANKIND PHARMA LTD (IN) 2018-01-17 EP disclosed
US-9862681-B2 N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives MANKIND RESEARCH CENTRE (IN) 2018-01-09 US disclosed
US-9862681-B2 N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives MANKIND RESEARCH CENTRE (IN) 2018-01-09 US disclosed
US-20160046577-A1 N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives MANKIND PHARMA LTD (IN) 2016-02-18 US disclosed
US-20160046577-A1 N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives MANKIND PHARMA LTD (IN) 2016-02-18 US disclosed
US-20160046577-A1 N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives MANKIND PHARMA LTD (IN) 2016-02-18 US disclosed
EP-2984070-A1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES Mankind Research Centre (IN) 2016-02-17 EP disclosed
WO-2014167507-A1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES MANKIND RESEARCH CENTRE (IN) 2014-10-16 WO disclosed
WO-2014167507-A1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES MANKIND RESEARCH CENTRE (IN) 2014-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10239833-B2 Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin ADRA1D, ADRB1, ADRA1A ADRA1D 1/4885ADRA1A 3/4885ADRA1B 5/4885
US-20160046577-A1 N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives ADRA1D, ADRA1A, ADRB1 ADRA1D 1/4885ADRA1A 2/4885ADRA1B 4/4885
US-20180111901-A1 Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin ADRA1D, ADRA1A, ADRB1 ADRA1D 1/4885ADRA1A 2/4885ADRA1B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.